FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890811159> ?p ?o ?g. }

• W2890811159 endingPage "73" @default.
• W2890811159 startingPage "65" @default.
• W2890811159 abstract "ABSTRACT Background Programmed cell death 1 (PD-1) is an inhibitory immune checkpoint expressed on activatedT cells. Upon the formation of T cell receptor (TCR)-pMHC complexes, concomitant PD-1 ligation to its ligands programmed death-ligand 1 (PD-L1) or programmed death-ligand 2 (PD-L2) downregulates TCR signaling and effector function. Here we describe the preclinical characterization of Sintilimab, a fully human IgG4 antibody that potently blocks PD-1 interactions with PD-L1 and PD-L2. Methods The binding affinity and blockade function were detected by using surface plasmon resonance (SPR), Enzyme-linked immunosorbent assay (ELISA) and flow cytometry. The biology function properties were measured with luciferase assay and mixed lymphocyte reaction assay. In vivo anti-tumor function and preclinical pharmacokinetic (PK) were identified with human PD-1 transgenic mice and non-human primates separately. Results Sintilimab can specifically and strongly bind to human PD-1 (hPD-1) and cynomolgus PD-1 and the affinity of Sintilimab to human PD-1 was measured at 0.3 nm via surface SPR, and displayed slow dissociation kinetics. Sintilimab can block the interaction of PD-1 to PD-L1 and PD-L2 and induce high secretion levels of interferon (IFN)-γ and interleukin (IL)-2 in primary T cell assays. In humanized hPD-1 knock-in mouse models, Sintilimab showed potent anti-tumor activity and increased tumor-infiltrating CD8/CD4 T cell and CD8/ Treg ratios. Preclinical experimentation in non-human primates following a single intravenous infusion of Sintilimab at 1, 6 and 30 mg/kg presented with no signs of drug-related toxicity, and showed typical PK characteristics of an IgG antibody. Conclusions Sintilimab has desirable preclinical attributes that supports its clinical development for cancer treatment." @default.
• W2890811159 created "2018-09-27" @default.
• W2890811159 creator A5002744113 @default.
• W2890811159 creator A5017753879 @default.
• W2890811159 creator A5026114982 @default.
• W2890811159 creator A5026339730 @default.
• W2890811159 creator A5029253557 @default.
• W2890811159 creator A5032277455 @default.
• W2890811159 creator A5044019415 @default.
• W2890811159 creator A5050789305 @default.
• W2890811159 creator A5053204257 @default.
• W2890811159 creator A5061644320 @default.
• W2890811159 creator A5064202722 @default.
• W2890811159 creator A5076343086 @default.
• W2890811159 creator A5084511556 @default.
• W2890811159 date "2018-09-01" @default.
• W2890811159 modified "2023-10-10" @default.
• W2890811159 title "Preclinical characterization of Sintilimab, a fully human anti-PD-1 therapeutic monoclonal antibody for cancer" @default.
• W2890811159 cites W1769186443 @default.
• W2890811159 cites W1971208896 @default.
• W2890811159 cites W1990779902 @default.
• W2890811159 cites W1994238092 @default.
• W2890811159 cites W1994993231 @default.
• W2890811159 cites W2004151829 @default.
• W2890811159 cites W2010121426 @default.
• W2890811159 cites W2017712207 @default.
• W2890811159 cites W2020031399 @default.
• W2890811159 cites W2063264144 @default.
• W2890811159 cites W2099609050 @default.
• W2890811159 cites W2101653483 @default.
• W2890811159 cites W2107752337 @default.
• W2890811159 cites W2111217091 @default.
• W2890811159 cites W2118471749 @default.
• W2890811159 cites W2123363005 @default.
• W2890811159 cites W2130207101 @default.
• W2890811159 cites W2130473166 @default.
• W2890811159 cites W2143772132 @default.
• W2890811159 cites W2156353875 @default.
• W2890811159 cites W2160834915 @default.
• W2890811159 cites W2279561773 @default.
• W2890811159 cites W2292383635 @default.
• W2890811159 cites W2332839490 @default.
• W2890811159 cites W2336443029 @default.
• W2890811159 cites W2339846251 @default.
• W2890811159 cites W2342094415 @default.
• W2890811159 cites W2342296008 @default.
• W2890811159 cites W2510686645 @default.
• W2890811159 cites W2578528809 @default.
• W2890811159 cites W2593714049 @default.
• W2890811159 cites W2606939149 @default.
• W2890811159 cites W4230861071 @default.
• W2890811159 doi "https://doi.org/10.1093/abt/tby005" @default.
• W2890811159 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7990132" @default.
• W2890811159 hasPublicationYear "2018" @default.
• W2890811159 type Work @default.
• W2890811159 sameAs 2890811159 @default.
• W2890811159 citedByCount "17" @default.
• W2890811159 countsByYear W28908111592018 @default.
• W2890811159 countsByYear W28908111592019 @default.
• W2890811159 countsByYear W28908111592020 @default.
• W2890811159 countsByYear W28908111592021 @default.
• W2890811159 countsByYear W28908111592022 @default.
• W2890811159 countsByYear W28908111592023 @default.
• W2890811159 crossrefType "journal-article" @default.
• W2890811159 hasAuthorship W2890811159A5002744113 @default.
• W2890811159 hasAuthorship W2890811159A5017753879 @default.
• W2890811159 hasAuthorship W2890811159A5026114982 @default.
• W2890811159 hasAuthorship W2890811159A5026339730 @default.
• W2890811159 hasAuthorship W2890811159A5029253557 @default.
• W2890811159 hasAuthorship W2890811159A5032277455 @default.
• W2890811159 hasAuthorship W2890811159A5044019415 @default.
• W2890811159 hasAuthorship W2890811159A5050789305 @default.
• W2890811159 hasAuthorship W2890811159A5053204257 @default.
• W2890811159 hasAuthorship W2890811159A5061644320 @default.
• W2890811159 hasAuthorship W2890811159A5064202722 @default.
• W2890811159 hasAuthorship W2890811159A5076343086 @default.
• W2890811159 hasAuthorship W2890811159A5084511556 @default.
• W2890811159 hasBestOaLocation W28908111591 @default.
• W2890811159 hasConcept C150903083 @default.
• W2890811159 hasConcept C153911025 @default.
• W2890811159 hasConcept C159654299 @default.
• W2890811159 hasConcept C167672396 @default.
• W2890811159 hasConcept C185592680 @default.
• W2890811159 hasConcept C19317047 @default.
• W2890811159 hasConcept C203014093 @default.
• W2890811159 hasConcept C207001950 @default.
• W2890811159 hasConcept C2776090121 @default.
• W2890811159 hasConcept C2777701055 @default.
• W2890811159 hasConcept C2781053074 @default.
• W2890811159 hasConcept C502942594 @default.
• W2890811159 hasConcept C542903549 @default.
• W2890811159 hasConcept C553184892 @default.
• W2890811159 hasConcept C86803240 @default.
• W2890811159 hasConcept C8891405 @default.
• W2890811159 hasConceptScore W2890811159C150903083 @default.
• W2890811159 hasConceptScore W2890811159C153911025 @default.
• W2890811159 hasConceptScore W2890811159C159654299 @default.
• W2890811159 hasConceptScore W2890811159C167672396 @default.

• next